TARO-GLICLAZIDE MR TABLET (EXTENDED-RELEASE)

Страна: Канада

Язык: английский

Источник: Health Canada

Активный ингредиент:

GLICLAZIDE

Доступна с:

SUN PHARMA CANADA INC

код АТС:

A10BB09

ИНН (Международная Имя):

GLICLAZIDE

дозировка:

60MG

Фармацевтическая форма:

TABLET (EXTENDED-RELEASE)

состав:

GLICLAZIDE 60MG

Администрация маршрут:

ORAL

Штук в упаковке:

15G/50G

Тип рецепта:

Prescription

Терапевтические области:

SULFONYLUREAS

Обзор продуктов:

Active ingredient group (AIG) number: 0119934003; AHFS:

Статус Авторизация:

APPROVED

Дата Авторизация:

2015-04-02

Характеристики продукта

_Pr_
_TARO-GLICLAZIDE MR (Gliclazide) Tablets - Product Monograph _
_ _
_Page 1 of 44 _
PRODUCT MONOGRAPH
PR
TARO-GLICLAZIDE MR
GLICLAZIDE
MODIFIED-RELEASE TABLETS
30 MG
MODIFIED-RELEASE BREAKABLE TABLETS
60 MG
Hypoglycemic sulfonylurea - Oral antidiabetic agent
Sun Pharma Canada Inc.
126 East Drive
Brampton, Ontario
L6T 1C1
Date of Revision:
March 11, 2020
Submission Control No.: 236213
_Pr_
_TARO-GLICLAZIDE MR (Gliclazide) Tablets - Product Monograph _
_ _
_Page 2 of 44 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
....................................................... 3
SUMMARY PRODUCT INFORMATION
.....................................................................
3
INDICATIONS AND CLINICAL USE
...........................................................................
3
CONTRAINDICATIONS
.................................................................................................
3
WARNINGS AND PRECAUTIONS
...............................................................................
4
ADVERSE REACTIONS
.................................................................................................
8
DRUG INTERACTIONS
...............................................................................................
13
DOSAGE AND ADMINISTRATION
...........................................................................
16
OVERDOSAGE
..............................................................................................................
18
ACTION AND CLINICAL PHARMACOLOGY
.......................................................... 18
STORAGE AND STABILITY
.......................................................................................
21
SPECIAL HANDLING INSTRUCTIONS
.....................................................................
21
DOSAGE FORMS, COMPOSITION AND PACKAGING
.......................................... 22
PART II: SCIENTIFIC INFORMATION
.............................................................................
23
PHARMACEUTICAL INFORMATION
...................